EP1742898A1 - Metal complexes based on tetrathiol ligands and their use in nuclear medical diagnostics and endoradionuclide therapy and method for producing said metal complexes - Google Patents
Metal complexes based on tetrathiol ligands and their use in nuclear medical diagnostics and endoradionuclide therapy and method for producing said metal complexesInfo
- Publication number
- EP1742898A1 EP1742898A1 EP05755479A EP05755479A EP1742898A1 EP 1742898 A1 EP1742898 A1 EP 1742898A1 EP 05755479 A EP05755479 A EP 05755479A EP 05755479 A EP05755479 A EP 05755479A EP 1742898 A1 EP1742898 A1 EP 1742898A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- metal complexes
- tetrathiol
- substituted
- mmol
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 23
- 239000002184 metal Substances 0.000 title claims abstract description 23
- 239000003446 ligand Substances 0.000 title claims abstract description 15
- NZARHKBYDXFVPP-UHFFFAOYSA-N tetrathiolane Chemical compound C1SSSS1 NZARHKBYDXFVPP-UHFFFAOYSA-N 0.000 title claims abstract description 13
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 title abstract description 5
- 125000003118 aryl group Chemical group 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 7
- 125000003277 amino group Chemical group 0.000 claims abstract 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims abstract 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims abstract 2
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000008139 complexing agent Substances 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 150000008064 anhydrides Chemical class 0.000 claims description 2
- 150000004985 diamines Chemical class 0.000 claims 1
- 230000021615 conjugation Effects 0.000 abstract description 3
- 101150009274 nhr-1 gene Proteins 0.000 abstract 2
- 101100295738 Gallus gallus COR3 gene Proteins 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 66
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- 239000007787 solid Substances 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 239000002244 precipitate Substances 0.000 description 25
- 239000000203 mixture Substances 0.000 description 22
- 239000011541 reaction mixture Substances 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000003480 eluent Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical compound [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 7
- 229910052702 rhenium Inorganic materials 0.000 description 7
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000012452 mother liquor Substances 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- -1 2,3-dimercapto-4-oxobutanoic acid Chemical compound 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000011877 solvent mixture Substances 0.000 description 5
- IZRAERNBXVOHGW-UHFFFAOYSA-N 2,2-dimethyl-1,3-dithiolane-4,5-dicarboxylic acid Chemical compound CC1(C)SC(C(O)=O)C(C(O)=O)S1 IZRAERNBXVOHGW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000012217 radiopharmaceutical Substances 0.000 description 4
- 229940121896 radiopharmaceutical Drugs 0.000 description 4
- 230000002799 radiopharmaceutical effect Effects 0.000 description 4
- 229910052713 technetium Inorganic materials 0.000 description 4
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 4
- FCNZISYCTIVCGE-UHFFFAOYSA-N 2,2-dimethyl-3a,6a-dihydro-[1,3]dithiolo[4,5-c]furan-4,6-dione Chemical compound O=C1OC(=O)C2C1SC(C)(C)S2 FCNZISYCTIVCGE-UHFFFAOYSA-N 0.000 description 3
- SLEKRJYNQGOWJS-UHFFFAOYSA-N 4-[2-[2-[[3-carboxy-2,3-bis(sulfanyl)propanoyl]amino]ethylamino]ethylamino]-4-oxo-2,3-bis(sulfanyl)butanoic acid Chemical compound OC(=O)C(S)C(S)C(=O)NCCNCCNC(=O)C(S)C(S)C(O)=O SLEKRJYNQGOWJS-UHFFFAOYSA-N 0.000 description 3
- MRRFNRRKDMQTKW-UHFFFAOYSA-N 4-[8-[[3-carboxy-2,3-bis(sulfanyl)propanoyl]amino]octylamino]-4-oxo-2,3-bis(sulfanyl)butanoic acid Chemical compound OC(=O)C(S)C(S)C(=O)NCCCCCCCCNC(=O)C(S)C(S)C(O)=O MRRFNRRKDMQTKW-UHFFFAOYSA-N 0.000 description 3
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 2
- ILAXBOIRSPXAMM-UHFFFAOYSA-N methyl n-aminocarbamodithioate Chemical compound CSC(=S)NN ILAXBOIRSPXAMM-UHFFFAOYSA-N 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 description 2
- 229940039790 sodium oxalate Drugs 0.000 description 2
- ACTRVOBWPAIOHC-UHFFFAOYSA-N succimer Chemical class OC(=O)C(S)C(S)C(O)=O ACTRVOBWPAIOHC-UHFFFAOYSA-N 0.000 description 2
- ACTRVOBWPAIOHC-XIXRPRMCSA-N succimer Chemical class OC(=O)[C@@H](S)[C@@H](S)C(O)=O ACTRVOBWPAIOHC-XIXRPRMCSA-N 0.000 description 2
- 229940056501 technetium 99m Drugs 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- PWGJDPKCLMLPJW-UHFFFAOYSA-N 1,8-diaminooctane Chemical compound NCCCCCCCCN PWGJDPKCLMLPJW-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- NJBCRXCAPCODGX-UHFFFAOYSA-N 2-methyl-n-(2-methylpropyl)propan-1-amine Chemical compound CC(C)CNCC(C)C NJBCRXCAPCODGX-UHFFFAOYSA-N 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- MEJAYWHSYKVVOY-UHFFFAOYSA-N [Re+5] Chemical compound [Re+5] MEJAYWHSYKVVOY-UHFFFAOYSA-N 0.000 description 1
- XVDFXDQCYAQYIK-UHFFFAOYSA-N [Tc+5] Chemical compound [Tc+5] XVDFXDQCYAQYIK-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- DYIZHKNUQPHNJY-UHFFFAOYSA-N oxorhenium Chemical compound [Re]=O DYIZHKNUQPHNJY-UHFFFAOYSA-N 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 238000003608 radiolysis reaction Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 150000003281 rhenium Chemical class 0.000 description 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
Definitions
- the invention relates to the field of radiopharmaceuticals, in particular metal complexes of tetrathiol ligands and their use as radioactive pharmaceuticals for diagnosis and in endoradionuclide therapy, as well as a method for producing the metal complexes.
- Rhenium isotopes are of interest for therapeutic use in endoradionuclide therapy.
- rhenium radiopharmaceuticals Another limiting factor in the development of rhenium radiopharmaceuticals is the lack of suitable complexing agents with which the radioactive metal can be stably coupled to biomolecules.
- the stability of many rhenium chelates with regard to hydrolysis, re-oxidation to perrhenate and radiolysis, which proceeds with the release of the radioactive metal from the target-binding radiopharmaceutical is inadequate for therapeutic use.
- dimercaptosuccinic acid has been proposed as agents for the labeling of proteins and antibodies with technetium-99m and rhenium-186 or rhenium-188 (US Pat. No. 5,175,256, 1992). This technical solution also does not lead to clearly defined connections. With regard to the stability criteria mentioned, the systems described and other systems do not yet meet the requirements for a broad in-vivo application.
- the object of the invention is to propose radiolytically and metabolically stable metal complexes which are suitable for conjugation with biomolecules and to specify a process for their preparation.
- the invention relates to the compounds described in claim 1, and to their use for binding radiometals, preferably technetium and rhenium, to biomolecules and a process for the preparation of the compounds according to claim 1.
- An important feature of the compounds according to the invention is that they have improved chemical and radiolytic stability compared to the known DMSA complexes with technetium and rhenium. Furthermore, the formation of isomers is controlled specifically by a special configuration of the complexing agent instead of the statistical isomer distribution in the known DMSA complexes.
- dimercaptosuccinic acid is used as a good complexing agent for technetium and rhenium.
- the general synthesis strategy is shown in Scheme 1.
- a new complexing agent is synthesized that contains four mercapto groups that are capable of coordinating with a metal, and this is reacted with technetium (V) or rhenium (V) to form the corresponding complex.
- the length of the carbon chain is chosen so that the mercapto groups are sterically favorable to the metal.
- An electron acceptor group (X) is built into the carbon chain, which further stabilizes the complex as a whole through interaction with the metal oxo group or the metal nitrido group. With this and through the choice of chain length, the formation of isomers can be controlled in a targeted manner.
- Biologically active units are coupled either via the electron acceptor group (X) or via the carboxyl groups (COOR).
- Example 1 4,4 '- (octane-1,8-diyldiimino) bis (2,3-dimercapto-4-oxobutanoic acid) (4)
- ligand 14 dissolved in a mixture of 0.5 ml of methanol and 0.2 ml of propylene glycol, is mixed with 1.0 ml of perrhenate generator eluate. After adding 1.0 mg of SnCl 2 , dissolved in 0.1 ml of 0.1
- Acetic acid and 28.0 mg sodium oxalate are mixed with 0.5 ml perrhenate generator eluate (10-30 mCi) and kept at room temperature for 15 min. Then the pH of the
- Tetrathiols 14 (1 mg in 0.25 ml methanol) are heated at 70 ° C. for 30 min. Radiochemical
- Acetic acid and 28.0 mg sodium oxalate are mixed with 0.5 ml pertechnetate generator eluate (10-30 mCi) and kept at room temperature for 15 min. Then the pH of the
- Tetrathiols 14 (1 mg in 0.25 ml methanol) are heated at 70 ° C. for 30 min. Radiochemical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004022461A DE102004022461B4 (en) | 2004-05-06 | 2004-05-06 | Metal complexes based on tetrathiol ligands and their application in nuclear medicine diagnostics and endoradione nuclide therapy as well as processes for the preparation of metal complexes |
PCT/DE2005/000868 WO2005108330A1 (en) | 2004-05-06 | 2005-04-28 | Metal complexes based on tetrathiol ligands and their use in nuclear medical diagnostics and endoradionuclide therapy and method for producing said metal complexes |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1742898A1 true EP1742898A1 (en) | 2007-01-17 |
Family
ID=34971256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05755479A Withdrawn EP1742898A1 (en) | 2004-05-06 | 2005-04-28 | Metal complexes based on tetrathiol ligands and their use in nuclear medical diagnostics and endoradionuclide therapy and method for producing said metal complexes |
Country Status (4)
Country | Link |
---|---|
US (1) | US7731936B2 (en) |
EP (1) | EP1742898A1 (en) |
DE (1) | DE102004022461B4 (en) |
WO (1) | WO2005108330A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004022461B4 (en) | 2004-05-06 | 2006-07-06 | Forschungszentrum Rossendorf E.V. | Metal complexes based on tetrathiol ligands and their application in nuclear medicine diagnostics and endoradione nuclide therapy as well as processes for the preparation of metal complexes |
DE102009029033A1 (en) | 2008-10-16 | 2010-06-24 | Forschungszentrum Dresden - Rossendorf E.V. | Tetrathiol ligands, metal complexes, conjugates and kits, their use in nuclear medicine diagnostics and endoradione nuclide therapy, as well as methods of making tetrathiol ligands and metal complexes |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0344724A2 (en) * | 1988-05-31 | 1989-12-06 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2092434A1 (en) * | 1990-09-27 | 1992-03-28 | Wolfgang J. Wrasidlo | Chelating agents |
US5175256A (en) | 1990-09-28 | 1992-12-29 | Neorx Corporation | Protein labeling reagents |
EP1072198B1 (en) | 1999-07-28 | 2008-05-14 | SWISS CAPS Rechte und Lizenzen AG | Preparation for use as medicament and/or nutritional supplement |
DE102004022461B4 (en) | 2004-05-06 | 2006-07-06 | Forschungszentrum Rossendorf E.V. | Metal complexes based on tetrathiol ligands and their application in nuclear medicine diagnostics and endoradione nuclide therapy as well as processes for the preparation of metal complexes |
-
2004
- 2004-05-06 DE DE102004022461A patent/DE102004022461B4/en not_active Expired - Fee Related
-
2005
- 2005-04-28 EP EP05755479A patent/EP1742898A1/en not_active Withdrawn
- 2005-04-28 WO PCT/DE2005/000868 patent/WO2005108330A1/en active Application Filing
- 2005-04-28 US US11/579,575 patent/US7731936B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0344724A2 (en) * | 1988-05-31 | 1989-12-06 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
Non-Patent Citations (1)
Title |
---|
See also references of WO2005108330A1 * |
Also Published As
Publication number | Publication date |
---|---|
US20080279770A1 (en) | 2008-11-13 |
WO2005108330A1 (en) | 2005-11-17 |
DE102004022461A1 (en) | 2005-12-01 |
US7731936B2 (en) | 2010-06-08 |
DE102004022461B4 (en) | 2006-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kasina et al. | Tissue distribution properties of technetium-99m-diamide-dimercaptide complexes and potential use as renal radiopharmaceuticals | |
AU2008203856B2 (en) | Stilbene derivatives and their use for binding and imaging amyloid plaques | |
US4670545A (en) | Chelating agents for technetium-99M | |
AU2002323417A1 (en) | Stilbene derivatives and their use for binding and imaging amyloid plaques | |
EP0692976B1 (en) | Chelating agents of the type xn 1?s 1?o 1? for radioactive isotopes, metal complexes thereof, and their use in diagnosis and therapy | |
US5496533A (en) | Rhenium complexes | |
DE60127951T2 (en) | SMALL TECHNETIUM 99M AND RHENIUM-MARKED MEANS AND METHOD FOR TUMOR IMAGING | |
EP0304780A1 (en) | Process for labelling substances with technetium or rhenium | |
EP1742898A1 (en) | Metal complexes based on tetrathiol ligands and their use in nuclear medical diagnostics and endoradionuclide therapy and method for producing said metal complexes | |
DE19860289C2 (en) | New chelators and their tricarbonyl complexes with technetium and rhenium | |
EP1836204B1 (en) | Radioactive metal complexes based on bispidine and derivatives thereof | |
EP0851770A2 (en) | Bifunctional sulphide-containing sulphonamide s 2?ny-type chelate-forming agents for radioisotopes | |
EP0692981B1 (en) | Chelators of type xn 1?s 1?x' for radioactive isotopes, their metal complexes and their diagnostic and therapeutical uses | |
Kuntschke et al. | New [99mTc]‐cytectrene amine compounds as specific brain imaging agents | |
EP0692980B1 (en) | Type s3n2 chelators for radioactive isotopes, their metal complexes and their diagnostic and therapeutical use | |
DE4025788C2 (en) | Technetium and rhenium complexes, process for their preparation and their use in diagnostics and therapy | |
US5997843A (en) | Radiometal complexes that localise in hypoxic tissue | |
Chiotellis et al. | Structure-activity relationships of some technetium-99m labeled [(thioethyl) amino] carboxylates | |
EP0588229A2 (en) | Macrocyclic chelating agents for the preparation of Technetium or Rhenium complexes | |
DE4425781A1 (en) | Technetium sulfonamide complexes, their use, pharmaceutical compositions containing them, and processes for the preparation of the complexes and compositions | |
WO2010043218A2 (en) | Tetrathiol ligands, metal complexes, conjugates, and kits, the use thereof in nuclear medicine diagnostics and endoradionuclide therapy, and method for producing the tetrathiol ligands and metal complexes | |
DD279024A1 (en) | METHOD FOR PRODUCING LIPOPHILES SULFUR COMPLEX COMPOUNDS OF THE TECHNETIUM | |
DE3218859A1 (en) | Amine derivatives of ruthenocene and ferrocene as radiopharmaceuticals | |
WO2004092184A1 (en) | Technetium-labelled fatty acids and their use in myocardial diagnostics, in addition to a method for producing said technetium-labelled fatty acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20061103 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: FORSCHUNGSZENTRUM DRESDEN - ROSSENDORF E.V. |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: FORSCHUNGSZENTRUM DRESDEN - ROSSENDORF E.V. |
|
17Q | First examination report despatched |
Effective date: 20090417 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: HELMHOLTZ-ZENTRUM DRESDEN - ROSSENDORF E.V. |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 51/00 20060101ALI20120202BHEP Ipc: C07C 323/60 20060101AFI20120202BHEP Ipc: A61K 51/04 20060101ALI20120202BHEP Ipc: A61P 35/00 20060101ALI20120202BHEP Ipc: C07B 59/00 20060101ALI20120202BHEP Ipc: C07F 13/00 20060101ALI20120202BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20120801 |